Harmony Biosciences Holdings, I

Valuation Analysis

About the Company

Harmony Biosciences Holdings, I en bref

Harmony Biosciences Holdings, I (HRMY) is currently trading at 29,01 € with a market capitalization of 1,7 Md €. The trailing P/E ratio stands at 13.42x, with a forward P/E of 5.96x. The 52-week range spans from 22,25 € to 35,63 €; the current price is 18.6% below the yearly high. Year-over-year revenue growth stands at +16.6%. The net profit margin stands at 16.2%.

💰 Dividende

Harmony Biosciences Holdings, I currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Harmony Biosciences Holdings, I (HRMY) au consensus : None. L'objectif de cours moyen est de 38,67 €, soit un potentiel de +33.3% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 24,41 € à 74,10 €.

Harmony Biosciences Holdings, I : la thèse d'investissement en détail

Harmony Biosciences Holdings, I (HRMY) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 16.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 76.55%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 16.2%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Short interest sits at 13.73% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 6.9x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 5.96x is meaningfully below the trailing 13.42x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 33.3% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (13.73%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Harmony Biosciences Holdings, I?

Compare top-rated brokers — low fees, trusted providers, fully regulated.